Open-label, Phase II Trial of Eribulin in Combination With Gemcitabine in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
Latest Information Update: 20 Jun 2022
At a glance
- Drugs Eribulin (Primary) ; Gemcitabine (Primary)
- Indications Leiomyosarcoma; Liposarcoma
- Focus Therapeutic Use
Most Recent Events
- 14 Jun 2022 Status changed from active, no longer recruiting to completed.
- 30 May 2022 Planned End Date changed from 30 Nov 2021 to 30 Nov 2022.
- 30 May 2022 Planned primary completion date changed from 30 Nov 2021 to 30 Nov 2022.